Ignite Biomedical
Ignite Biomedical is at the forefront of precision medicine, developing AI-driven biomarker blood tests to predict patient response to specific therapies, thereby reducing waste and improving outcomes in healthcare. The company's core product is a Therapeutic Response Predictor (TRP) blood test. Their approach leverages AI and deep clinical expertise to identify objective predictors of drug response prior to treatment initiation. Key differentiators include high accuracy (sensitivity and specificity above 90%), speed from discovery to test development in months, and reproducibility using AI-based technology. Ignite Biomedical's pipeline focuses on immunology, with specific tests for TNFi therapy response across indications like Inflammatory Bowel Disease (IBD), Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis. They also plan to expand into Behavioral Medicine and Neurology. Their business model includes direct distribution through their lab, SmartHealth Diagnostics, and licensing to other labs and healthcare providers. The company aims to make these tests widely accessible to physicians and patients.
Ignite Biomedical
Ignite Biomedical is at the forefront of precision medicine, developing AI-driven biomarker blood tests to predict patient response to specific therapies, thereby reducing waste and improving outcomes in healthcare. The company's core product is a Therapeutic Response Predictor (TRP) blood test. Their approach leverages AI and deep clinical expertise to identify objective predictors of drug response prior to treatment initiation. Key differentiators include high accuracy (sensitivity and specificity above 90%), speed from discovery to test development in months, and reproducibility using AI-based technology. Ignite Biomedical's pipeline focuses on immunology, with specific tests for TNFi therapy response across indications like Inflammatory Bowel Disease (IBD), Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis. They also plan to expand into Behavioral Medicine and Neurology. Their business model includes direct distribution through their lab, SmartHealth Diagnostics, and licensing to other labs and healthcare providers. The company aims to make these tests widely accessible to physicians and patients.